Tag: proteogenomics

Research Context

• No human interventional trials of P21 are included in the supplied packet, and no cited study directly evaluates P21 in humans. The packet’s own uncertainties emphasize “little or no direct human evidence.”
• Although the packet’s claims field suggests that “direct human evidence exists,” the provided citations do not substantiate human efficacy for P21. We resolve this internal inconsistency conservatively: human efficacy and safety for P21 remain unestablished in this packet.
• Several citations are not P21-specific. They illuminate broader themes (e.g., proteogenomic target discovery, KRAS-directed platforms, chemical-biology tools) that are contextual to peptide research rather than direct evidence about P21.
• The pan-cancer proteogenomic work (pubmed:38917788) is a target-identification/characterization resource using human tumor data. It does not report clinical outcomes and should not be treated as a review.

Direct Answer

Based on the supplied literature, there are no human interventional studies of P21, and no paper in the packet directly tests P21 in humans. The evidence base presented is predominantly preclinical and contextual (proteogenomic target discovery, KRAS-focused engineering and mechanistic studies, senescence and fibrosis models, chemical-biology tools). Any human relevance in this packet pertains to target landscapes or engineered platforms in oncology—not to clinical efficacy or safety of P21.

Human evidence and contextual resources (not P21 efficacy)

• Pan-cancer proteogenomics expands the therapeutic target landscape (pubmed:38917788). This is a human tumor characterization resource without clinical outcome data and without P21-specific clinical testing.
• KRAS-focused development efforts (e.g., mutant KRAS peptide–targeted CAR-T engineering and orally bioavailable intracellular peptide programs: pubmed:40480232; pubmed:37463267) are translational/engineering in nature, not human trials of P21.

Preclinical and mechanistic evidence

• KRAS-directed platforms and mechanisms:
• Structure–activity relationships for middle-size cyclic peptides that inhibit KRAS, derived from mRNA display (pubmed:38981216).
• A covalent KRAS(G12C) inhibitor that induces MHC class I presentation of haptenated peptide neoepitopes, with implications for immunotherapy targeting (pubmed:36099883).
• A KRAS G12V neoantigen–specific T cell receptor engineered for adoptive T-cell therapy (pubmed:37828002).
• Fibrosis and cellular senescence:
• A Klotho-derived peptide inhibits cellular senescence in a fibrotic kidney model by restoring Klotho expression via posttranscriptional regulation (preclinical/mechanistic; pubmed:38164143).
• Cognition model:
• A recombinant walnut-derived peptide ameliorates d-galactose–induced cognitive deficits in a preclinical model (pubmed:40864666).

Tools, target validation, and infrastructure (not clinical efficacy)

• A turn-on fluorescent PCNA sensor (chemical-biology tool; modality not specified as peptide in the citation metadata; pubmed:33839250).
• A PAK4-targeting PROTAC developed for renal carcinoma therapy that both inhibits cancer cell proliferation and enhances immune cell responses (small-molecule chimera concept; target-validation/drug-design context; pubmed:38810561).

Evidence-tier mapping (by citation)

• pubmed:38917788 — Human tumor proteogenomic target-identification/characterization; no clinical outcomes; not P21-specific.
• pubmed:40480232 — Mutant KRAS peptide–targeted CAR-T engineering; preclinical/engineering; not P21.
• pubmed:37463267 — Development of orally bioavailable peptides to an intracellular KRAS inhibitor; medicinal chemistry/translation pathway; not P21; not clinical efficacy.
• pubmed:37828002 — Engineered TCR against KRAS G12V neoantigen; preclinical/engineering; not P21.
• pubmed:38164143 — Klotho-derived peptide reduces senescence in fibrotic kidney model; preclinical/mechanistic; not P21.
• pubmed:36099883 — KRAS(G12C) covalent inhibitor induces haptenated neoepitopes; mechanistic tumor immunology; preclinical; not P21.
• pubmed:40864666 — Recombinant walnut-derived peptide in d-galactose–induced cognitive deficit model; preclinical; not P21.
• pubmed:33839250 — Turn-on fluorescent PCNA sensor; chemical-biology tool; modality not specified as peptide; not P21.
• pubmed:38981216 — SAR of middle-size cyclic peptides as KRAS inhibitors from mRNA display; preclinical; not P21.
• pubmed:38810561 — PAK4-targeting PROTAC; small-molecule chimera; target-validation/drug-design; preclinical; not P21.

Limitations and scope boundaries

• No direct human efficacy or safety data for P21 are provided.
• Dosing, generalized safety, and off-label extrapolation are not supported by the packet.
• Broad anti-aging or wellness claims are unsupported.
• Mechanistic or platform-level findings (e.g., senescence modulation, neoantigen presentation, proteogenomic target expansion) should not be generalized to P21 clinical utility.

References

1. pubmed:38917788 — Pan-cancer proteogenomics expands the landscape of therapeutic targets. https://pubmed.ncbi.nlm.nih.gov/38917788/ 2. pubmed:40480232 — Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. https://pubmed.ncbi.nlm.nih.gov/40480232/ 3. pubmed:37463267 — Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor. https://pubmed.ncbi.nlm.nih.gov/37463267/ 4. pubmed:37828002 — KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. https://pubmed.ncbi.nlm.nih.gov/37828002/ 5. pubmed:38164143 — Klotho-derived peptide 1 inhibits cellular senescence in the fibrotic kidney by restoring Klotho expression via posttranscriptional regulation. https://pubmed.ncbi.nlm.nih.gov/38164143/ 6. pubmed:36099883 — A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. https://pubmed.ncbi.nlm.nih.gov/36099883/ 7. pubmed:40864666 — Recombinant Walnut-Derived Peptide Ameliorates d-Galactose-Induced Cognitive Deficits. https://pubmed.ncbi.nlm.nih.gov/40864666/ 8. pubmed:33839250 — A turn-on fluorescent PCNA sensor. https://pubmed.ncbi.nlm.nih.gov/33839250/ 9. pubmed:38981216 — Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display. https://pubmed.ncbi.nlm.nih.gov/38981216/ 10. pubmed:38810561 — Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. https://pubmed.ncbi.nlm.nih.gov/38810561/

Research-use-only catalog access

KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.